Long-term safety of icotinib in patients with non-small cell lung cancer: a retrospective, real-world study

• DOI: 10.21037/jtd.2019.12.115
• Publication Date: 2020-03-23T00:47:17Z
• Authors: Wen Zhang; Yiping Zhang; Qiong Zhao; Xiguang Liu; Likun Chen; Hongming Pan; Yuping Li; You Lu; Jianjin Huang; Zhe Zhang; Kaiqi Du; Suning Zhang; Tao Li; Liqin Lu; Guangmao Yu; Yang Wang; Xiaobin Yuan; Min Yang; Yongbin Ma; Fenlai Tan
• Keywords: Clinical endpoint

Lung cancer is a global health problem with high mortality, and the development of target therapy has led to revolution in treatment lung recent years. Favorable efficacy safety icotinib have been demonstrated patients non-small cell (NSCLC). Currently, minimal data are available describe long-term NSCLC patients.We reviewed from 1,321 advanced who were treated icotinib. The primary endpoint was safety, defined as any adverse drug reactions (ADRs) occurred after 6 months administration.Fewer ADRs noticed over month administration than within overall population (24.3% vs. 65.4%), elderly (23.6% 66.9%). majority grade 1-2 severity exposure well patients. In population, most common during use rash (16.4%) diarrhea (5.3%), while incidences 31.8% 13.2% induction period, respectively. (15.7%) (4.7%), 27.8% 14.9% respectively, more inching observed period compared long term (6.3% 0.3%).There an evidence decreased frequency icotinib-induced time, well-tolerated